ADINAZOLAM MESYLATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H18ClN5.CH4O3S
Molecular Weight	447.938
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CN(C)CC1=NN=C2CN=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N12

InChI

InChIKey=FENBITQPWFCMEB-UHFFFAOYSA-N

InChI=1S/C19H18ClN5.CH4O3S/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18;1-5(2,3)4/h3-10H,11-12H2,1-2H3;1H3,(H,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6320036 | https://www.ncbi.nlm.nih.gov/pubmed/3298327 | https://www.ncbi.nlm.nih.gov/pubmed/9600717 | https://www.ncbi.nlm.nih.gov/pubmed/27535017

Adinazolam, a benzodiazepine agonist, is an effective anxiolytic agent with antidepressant properties. It was shown, that adinazolam by itself had relatively weak benzodiazepine agonist activity, and much of the pharmacological activity belonged to its active metabolite N-desmethyladinazolam (NDMAD). Adinazolam has never been FDA approved, but it is sold as a research chemical.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABA-A receptor; benzodiazepine site 38 Target ID: CHEMBL2109243 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6148400	Agonist 2678

PubMed

Title	Date	PubMed
Regulation of serotonin type 2 (5-HT2) and beta-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment.	1991 Nov	1664741
Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.	1998 Mar	9600717
A follow-up study of DSM-III-R generalized anxiety disorder with syndromal and subsyndromal major depression.	2003 Feb	12547291
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.	2003 Feb 28	12600700
Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.	2007 Jul	17481865
Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.	2009 Jun	19430911

Patents

Sample Use Guides

In Vivo Use Guide

from 90 to 40 mg/day.

Route of Administration: Oral

Name

Type

Language

ADINAZOLAM MESYLATE

Official Name

English

ADINAZOLAM MESYLATE [USAN]

Common Name

English

4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE-1-METHANAMINE, 8-CHLORO-N,N-DIMETHYL-6-PHENYL-, MONOMETHANESULFONATE

Systematic Name

English

4H-(1,2,4)TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE-1-METHANAMINE, 8-CHLORO-N,N-DIMETHYL-6-PHENYL-, MONOMETHANESULPHONATE

Systematic Name

English

ADINAZOLAM METHANESULFONATE [MI]

Common Name

English

ADINAZOLAM METHANESULFONATE

Common Name

English

8-Chloro-1-[(dimethylamino)methyl]-6-phenyl-4H-S-triazolo[4,3-a][1,4]benzodiazepine monomethanesulfonate

Systematic Name

English

U-41,123F

Code

English

ADINAZOLAM MESILATE [MART.]

Common Name

English

ADINAZOLAM MESILATE

Common Name

English

U-41123F

Code

English

8-CHLORO-1-((DIMETHYLAMINO)METHYL)-6-PHENYL-4H-S-TRIAZOLO(4,3-A)(1,4)BENZODIAZEPINE MONOMETHANESULPHONATE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1012